Mercy Corps gets Donation of $10 million from Ripple (XRP) to Expand its Financial Inclusion

Mercy Corps gets Donation of $10 million from Ripple (XRP) to Expand its Financial Inclusion

Mercy Corps which is a humanitarian aid non-profit organization is going to get a donation of $10 million from Ripple (XRP), the U.S.-based currency exchange, and a remittance network. This donation will help Mercy Corps to expand its financial inclusion and increase the economic capacities globally. Being a non-profit organization, the core purpose of Ripple is to work with non-government organizations, universities, and industry partners to introduce the 1.7 billion unbanked individuals into an updated…

Read More

IBM Enters Esports Arena with Activision Blizzard in New Multi-Year Deal as the Presenting Partner of the Overwatch League Grand Finals

Today, IBM and the Overwatch League™, the world’s first global esports league with 20 city-based teams, announced its first-of-a-kind multi-year deal to bring IBM’s cloud computing and artificial intelligence (AI) technology to esports. A sponsorship component kicks off at this year’s 2020 Overwatch League Grand Finals, which started Oct. 8 and run through Oct. 10. With the agreement – IBM’s first-ever esports deal – the technology leader becomes the official AI, cloud, and analytics sponsor of the Overwatch League. The deal…

Read More

U.S. General Services Administration (GSA) Deploys BIO-key’s PortalGuard Identity and Access Management (IAM) Solution for Two-factor Authentication Compliance

 BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions powered by biometrics, today announced that the U.S. General Services Agency (GSA), which provides centralized procurement for the federal government, selected BIO-key’s PortalGuard IAM solution to deliver flexible, secure and compliant two-factor authentication for a public facing central communication application. The Office of GSA Information Technology (OGIT) administers a publicly accessible electronic mailing list environment and has a security requirement to…

Read More

Aduro Biotech Inc. (ADRO) Announces Approval of Merger Agreement with Chinook Therapeutics by Shareholders

Aduro Biotech Inc. (ADRO) Announces Approval of Merger Agreement with Chinook Therapeutics by Shareholders

Aduro Biotech, Inc. (ADRO) on Oct. 01, 2020 reported the results for the three proposals considered and voted upon by its stockholders at its Special Meeting on October 1, 2020. The Company reported that the various proposals giving effect to the merger agreement between Aduro and Chinook Therapeutics were approved by approximately 55,168,606 of the outstanding shares of Aduro. All proposals were approved by the Aduro stockholders. A Form 8-K disclosing the full voting results…

Read More

Solid Biosciences Inc. (SLDB) Surged 70.44% After FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial

Solid Biosciences Inc. (SLDB) Surged 70.44% After FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial

Solid Biosciences Inc. (SLDB) shares soared 70.44% after news announced on October 1, 2020, that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Company’s IGNITE DMD Phase I/II clinical trial. The FDA had asked for more manufacturing information, updated safety and efficacy data for all patients dosed, and provided direction on total viral load to be administered per patient. Based on the Company’s response to these requests, the…

Read More

FuelCell Energy Declares Pricing of Offering of Common Stock

FuelCell Energy Declares Pricing of Offering of Common Stock

FuelCell Energy, Inc. (FCEL) on Sept. 29, 2020 publicized the pricing of its underwritten public offering of 43,500,000 shares of its common stock, at a public offering price of $2.10 per share, for gross proceeds of approximately $91,350,000. The Offering is expected to close on or about October 2, 2020, subject to customary closing conditions. FuelCell Energy has also settled the underwriters a 30-day option to buy up to 6,525,000 additional shares of its common…

Read More

Adial Pharmaceuticals(ADIL) Announces Emergency Use Approval (EUA) For Assure/FaStep® COVID-19 By FDA

Adial Pharmaceuticals(ADIL) Announces Emergency Use Approval (EUA) For Assure/FaStep® COVID-19 By FDA

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) revealed on September 29, 2020, that the U.S. Food and Drug Administration (FDA) has given a emergency use approval (EUA) for the Assure/FaStep® COVID-19 IgG/IgM Rapid Test Device. This denotes the principal FDA EUA for a serology (immunizer) purpose of-care (POC) test for COVID-19 utilizing fingerstick blood tests as contrasted and current endorsed tests that use just for serum, plasma, or a venous blood draw. Because of the FDA’s EUA, fingerstick…

Read More

Let’s Take a Look at Wave Life Sciences Ltd. (WVE) Stock After Prices $100 Million Public Offering of Ordinary Shares

Let’s Take a Look at Wave Life Sciences Ltd. (WVE) Stock After Prices $100 Million Public Offering of Ordinary Shares

Wave Life Sciences Ltd. (WVE) announced on September 23, 2020, the pricing of its earlier reported underwritten public offering of 8,333,334 of its ordinary shares at a price to the public of $12.00 per ordinary share. Gross profits to Wave Life Sciences from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by Wave Life…

Read More

Is it Time to Sell/Buy MediciNova Inc. (MNOV) Stock After Recent Trade?

Is it Time to Sell/Buy MediciNova Inc. (MNOV) Stock After Recent Trade?

MediciNova Inc. (MNOV) today declared positive clinical findings published in Cancer Chemotherapy and Pharmacology regarding MN-166 (ibudilast) as a treatment for prevention of chemotherapy-induced peripheral neuropathy (CIPN). The publication, entitled “Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability, and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer”, is the result of a collaborative effort between MediciNova and Dr. Janette Vardy, Professor of Cancer Medicine, University of Sydney Concord Cancer…

Read More

Digital Ally Inc. (DGLY) Receives A Notable Order For ThermoVu™ Non-Contact Temperature Screening Devices

Digital Ally Inc. (DGLY) Receives A Notable Order For ThermoVu™ Non-Contact Temperature Screening Devices

Digital Ally, Inc. (NASDAQ: DGLY) on September 21, 2020 declared that the company received a remarkable order for KS for 42 ThermoVu™ non-contact temperature screening devices from Linn County. Linn County represents the first municipality to deploy ThermoVuä units county-wide. The units will be put in the courthouse, county offices, senior centers, parks/marinas, schools, and other populated public areas to detect high temperatures in staff and visitors. ThermoVuä was launched recently as a non-contact temperature-measuring…

Read More
1 2 3 6